Proteomics International Laboratories launches PromarkerD predictive test for diabetic kidney disease
Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia.
PromarkerD is a clinically validated blood test that helps predict the risk of developing chronic diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear.
Diabetes is the leading cause of chronic kidney disease globally and the burden is particularly acute in Australia, where more than 1.3 million people are living with the condition.
Importance of early diagnosis
Managing director Dr Richard Lipscombe said the ability to obtain an early intervention window would enable better patient management while reducing the risk of severe kidney complications, including renal failure and the need for dialysis or transplant.
“We are excited to officially launch PromarkerD in Australia, particularly on World Kidney Day, which underscores the importance of early diagnosis and prevention,” Dr Lipscombe said.
“DKD is a major public health challenge and PromarkerD offers a highly innovative, accurate and accessible way to identify those most at risk.”
“By enabling proactive management, we aim to reduce the personal and financial costs associated with this life-threatening condition.”
Key stakeholder discussions
The launch supports Proteomics International’s plans to achieve the widespread adoption of PromarkerD across Australia.
The company is currently engaging with key stakeholders across local primary care networks, diabetes clinics and professional bodies.
It aims to collaborate with health insurers, patient advocacy groups and government bodies to explore potential reimbursement pathways.
The test will initially be available through a direct-to-consumer go-to-market route as a prelude to out-licensing to major industry players in the diagnostics sector.
Landmark study published
Proteomics reported earlier this week that the results from a landmark study into the benefits of PromarkerD had been published in a significant medical journal.
The study confirmed that PromarkerD can significantly outperform the current standard-of-care tests in predicting future kidney function decline in type 2 diabetics.
The results were published in the peer-reviewed journal Diagnostics in a paper titled “PromarkerD Versus Standard of Care Biochemical Measures for Assessing Future Renal Function Decline in Type 2 Diabetes”.
“This peer-reviewed comparison against the standard of care is critical in proving the power of PromarkerD to the medical community,” Dr Lipscombe said.
“We want to provide healthcare professionals with the best tools available to combat this debilitating disease.”